Jump to content

DTP-HepB vaccine

From Wikipedia, the free encyclopedia
DTP-HepB
Combination of
DTP vaccineVaccine
Hepatitis B vaccineVaccine
Clinical data
Trade namesTritanrix-HepB
AHFS/Drugs.comUK Drug Information
Routes of
administration
Intramuscular injection
ATC code
Identifiers
CAS Number

DTP-HepB vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis and hepatitis B (recombinant) vaccine (adsorbed) or DTP-Hep B. It protects against the infectious diseases diphtheria, tetanus, pertussis, and hepatitis B.[1]

A branded formulation, Tritanrix-HepB manufactured by GlaxoSmithKline, was granted marketing approval in the EU in 1996. Marketing approval lapsed in 2014.[2]

A review conducted in 2012 concluded that there was insufficient evidence to determine differences in safety and efficacy between DTP-HepB vaccine and Hib vaccine administered separately and pentavalent DTP-HepB-Hib vaccine.[3]

References

[edit]
  1. ^ World Health Organization; World Health Organization Department of Immunization, Vaccines and Biologicals (2004). Immunization in Practice: A Practical Guide for Health Staff. World Health Organization. p. 18. ISBN 9789241546515. Retrieved 15 July 2018.
  2. ^ "Tritanrix HepB". European Medicines Agency. Archived from the original on 15 July 2018. Retrieved 14 July 2018.
  3. ^ Bar-On ES, Goldberg E, Hellmann S, Leibovici L (April 2012). "Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)". The Cochrane Database of Systematic Reviews. 4 (4): CD005530. doi:10.1002/14651858.CD005530.pub3. PMID 22513932.